{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:48:27Z","timestamp":1793393307551,"version":"4.5.0"},"reference-count":48,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2018,1,3]],"date-time":"2018-01-03T00:00:00Z","timestamp":1514937600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"The Canadian Urological Association-Pfizer Urology Resident Grant Program"},{"name":"The Canadian Drug Safety & Effectiveness Research Network (CDSERN)"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intl Journal of Cancer"],"published-print":{"date-parts":[[2018,5]]},"abstract":"<jats:p>Several studies demonstrate that use of commonly prescribed medications is associated with improved survival in various malignancies. Methods of classifying medication use in many of these studies, however, do not account for intermittent or cumulative use. Moreover, there are limited data in kidney cancer. Therefore, we performed a population\u2010based cohort study utilizing healthcare databases in Ontario, Canada. We identified patients aged \u226565 with an incident diagnosis of kidney cancer between 1997 and 2013 and examined use of nine putative anti\u2010neoplastic medications using prescription claims. Cox proportional hazard models evaluated the association of medication exposure on cancer\u2010specific and overall survival. We conducted three separate analyses: the effect of cumulative duration of exposure to the study medications on outcomes, the effect of current exposure (in a binary nature) and the effect of exposure at diagnosis. During the 16\u2010year study period, we studied 9,124 patients. Increasing cumulative use of angiotensin\u2010converting enzyme inhibitors, non\u2010steroidal anti\u2010inflammatory drugs (NSAIDs) and selective serotonin reuptake inhibitors were associated with markedly improved cancer\u2010specific survival; increasing use of NSAIDs was associated with markedly improved overall survival. These results were generally discordant with analyses evaluating the effect of current use and exposure at diagnosis. In conclusion, pharmacoepidemiology studies may be sensitive to the method of analysis; cumulative use analyses may be the most robust as it accounts for intermittent use and supports a dose\u2013outcome relationship. Prospective studies are needed to confirm whether patients diagnosed with kidney cancer should be started on an angiotensin\u2010converting enzyme inhibitor, NSAID or selective serotonin reuptake inhibitor to improve survival.<\/jats:p>","DOI":"10.1002\/ijc.31204","type":"journal-article","created":{"date-parts":[[2017,12,11]],"date-time":"2017-12-11T08:19:59Z","timestamp":1512980399000},"page":"1776-1785","source":"Crossref","is-referenced-by-count":15,"title":["Medication use and kidney cancer survival: A population\u2010based study"],"prefix":"10.1002","volume":"142","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7502-3475","authenticated-orcid":false,"given":"Madhur","family":"Nayan","sequence":"first","affiliation":[{"name":"Division of Urology, Departments of Surgery and Surgical Oncology Princess Margaret Cancer Centre, University Health Network and the University of Toronto Toronto Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David N.","family":"Juurlink","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Sunnybrook Health Sciences Centre, University of Toronto Toronto Canada"},{"name":"Institute for Clinical Evaluative Sciences Toronto Canada"},{"name":"Institute of Health Management, Policy and Evaluation, University of Toronto, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.","family":"Austin","sequence":"additional","affiliation":[{"name":"Institute for Clinical Evaluative Sciences Toronto Canada"},{"name":"Institute of Health Management, Policy and Evaluation, University of Toronto, Toronto, Canada"},{"name":"Schulich Heart Research Program, Sunnybrook Research Institute Toronto Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin M.","family":"Macdonald","sequence":"additional","affiliation":[{"name":"Institute for Clinical Evaluative Sciences Toronto Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Finelli","sequence":"additional","affiliation":[{"name":"Division of Urology, Departments of Surgery and Surgical Oncology Princess Margaret Cancer Centre, University Health Network and the University of Toronto Toronto Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Girish S.","family":"Kulkarni","sequence":"additional","affiliation":[{"name":"Division of Urology, Departments of Surgery and Surgical Oncology Princess Margaret Cancer Centre, University Health Network and the University of Toronto Toronto Canada"},{"name":"Institute for Clinical Evaluative Sciences Toronto Canada"},{"name":"Institute of Health Management, Policy and Evaluation, University of Toronto, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Hamilton","sequence":"additional","affiliation":[{"name":"Division of Urology, Departments of Surgery and Surgical Oncology Princess Margaret Cancer Centre, University Health Network and the University of Toronto Toronto Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Canadian Drug Safety and Effectiveness Research Network (CDSERN)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,1,3]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.10.002"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2010.46"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10552-014-0427-x"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv147"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2332"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70112-2"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-006-9277-x"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10552-007-9003-y"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.33.5422"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.01.007"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2013.09.001"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.3243"},{"key":"e_1_2_7_14_1","first-page":"3691","article-title":"Fluoxetine\u2010induced apoptosis in hepatocellular carcinoma cells","volume":"33","author":"Mun A\u2010R","year":"2013","journal-title":"Anticancer Res"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1201735"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1158\/1940-6207.CAPR-14-0002"},{"key":"e_1_2_7_17_1","unstructured":"LangleyRE WilsonRH RingAE et al. Add\u2010Aspirin trial: a phase III double blind placebo\u2010controlled randomized trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common nonmetastatic solid tumors. ASCO Annual Meeting Proceedings http:\/\/ascopubs.org\/doi\/abs\/10.1200\/jco.2014.32.15_suppl.tps1617"},{"key":"e_1_2_7_18_1","unstructured":"Samsung Medical C. Capecitabine Plus Simvastatin in Locally Advanced Rectal Cancer Patients.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02161822."},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwm324"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21661"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyp089"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2013.10.141"},{"key":"e_1_2_7_23_1","doi-asserted-by":"crossref","first-page":"21.e11\u2013e7","DOI":"10.1016\/j.urolonc.2014.10.007","article-title":"Statin use is associated with improved survival in patients undergoing surgery for renal cell carcinoma","volume":"33","author":"Kaffenberger SD","year":"2015","journal-title":"Urol Oncol"},{"key":"e_1_2_7_24_1","doi-asserted-by":"crossref","first-page":"487.e1\u2013e6","DOI":"10.1016\/j.urolonc.2016.06.007","article-title":"Statin use and kidney cancer survival outcomes: a propensity score analysis","volume":"34","author":"Nayan M","year":"2016","journal-title":"Urol Oncol"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2016.06.008"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2016.11.009"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-015-4436-0"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2016.09.027"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djr145"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju424"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.7043"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwp107"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0b013e318215d5e2"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2016.04.004"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.3511"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.07.001"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.10.034"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.4564"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1177\/003591576505800503"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1998.145"},{"key":"e_1_2_7_41_1","first-page":"4176","article-title":"Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis","volume":"62","author":"Miyajima A","year":"2002","journal-title":"Cancer Res"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2007.01.071"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2006.06056.x"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)67288-4"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2010.47"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2017.05.007"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-2535"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.2517-6161.1995.tb02031.x"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1454"}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fijc.31204","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.31204","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T14:04:07Z","timestamp":1695650647000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.31204"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,3]]},"references-count":48,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["10.1002\/ijc.31204"],"URL":"https:\/\/doi.org\/10.1002\/ijc.31204","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"value":"0020-7136","type":"print"},{"value":"1097-0215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,3]]}}}